Complement and IL-6 pathways have been implicated in anti-GBM pathogenesis, supporting consideration of IL-6 blockade for RA control on a case-by-case basis; importantly, no causal link to TNF-α inhibitors has been established. Here, TNF is linked to rheumatoid arthritis.